Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
about
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationIncretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseDPP4 in DiabetesNon-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityPromising therapies for treatment of nonalcoholic steatohepatitis.Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionIngestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretionGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Dietary combination of sucrose and linoleic acid causes skeletal muscle metabolic abnormalities in Zucker fatty rats through specific modification of fatty acid composition.Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemFocus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration.The pathophysiology of hypertension in patients with obesity.Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.Effect of vildagliptin on hepatic steatosis.Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function.Inhibitory effects of Doenjang, Korean traditional fermented soybean paste, on oxidative stress and inflammation in adipose tissue of mice fed a high-fat diet.Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian SubjectsPleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid.Differentiation of human adipocytes at physiological oxygen levels results in increased adiponectin secretion and isoproterenol-stimulated lipolysis.Dipeptidyl peptidase-4: a key player in chronic liver disease.DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Innate immune activation in obesity.Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.Cardiovascular effects of the DPP-4 inhibitors.
P2860
Q26778329-22434025-23C9-4002-A3F6-7FDE92A7D73DQ26784211-7E09B516-EEAF-449F-B152-8BB7284431BEQ26797335-C45E3C88-D1E0-4588-834F-6C26CBCB1644Q26800894-12038B08-E63D-4173-9110-23B1BFE15692Q27006992-1DAD9024-2C17-46EC-91EA-6E8CEB15B803Q27011819-0F99976D-322A-4E21-9B48-B1C2189B86D2Q28728101-930F7497-75BF-4772-8133-61A3FA658786Q30248578-B260DEFC-744B-40CF-B817-7A0CAEC8CF97Q30717371-05176C67-A8CB-4B80-B07F-CA38472550B7Q33603296-7A6F0A11-5561-4A9A-B971-3AF2327497C1Q33603384-ABF1EC7D-AC84-4F79-B446-AF674ED9B96AQ33610654-A39756BC-C08A-450B-9104-714A32868319Q33802278-BCB64F7F-931B-4472-BD79-38A5435123E1Q33832051-71E886C8-B82C-4E22-9FAF-B28BFA09BCDEQ33970970-FFDA150C-BA97-421D-96BD-FD8D52920D9AQ34062829-35D30BBD-A898-4205-B774-E3C41F3A7667Q34647400-8359402F-8229-447C-B699-BCC6B6AA404BQ34733928-558B36C8-D8EC-4A8B-B740-CB1C0F8A9897Q34746178-DD3A7D62-56EE-4382-9D4A-4BCFBA059310Q35021492-38716576-D790-441F-81FA-0F78445FEE91Q35192176-8FB19808-4799-4E8F-A4C0-A9E1B2E5F958Q35285238-11B76B1B-8339-41F7-A1AC-6E01B0118932Q35413944-CAA094EE-A27E-439C-A95D-480B689F09C2Q35442079-357207ED-02F7-48B2-B672-F433B2615539Q35630861-89B6A3D6-943E-4FF8-8A35-D0B8E8A3F540Q35696782-A69218CF-261F-4CA3-9421-8E2A8E56F374Q36170755-FF6C55B3-B887-403D-9A3D-49499D9686F7Q36254518-3C257F20-A1D4-4A98-BAEB-6A35EB28ADA4Q36465496-2FB4CB4B-977E-40AE-94F3-BA19A3DB8DF2Q36639293-56FAFE32-CAF7-47B6-A99F-4E70A1DA3E2DQ36719115-E5C47CB2-5BAB-45ED-8C3A-5CB2B7D2D7F6Q36783164-B36A4C48-B408-4995-BE3E-6100BCED353FQ37095161-10D090F6-9E41-43D6-BCE5-45436562AAEFQ37258157-DA50DCFE-BB68-4449-8E2C-CBAE43F7778DQ37331331-BBE3056E-A3C6-4374-844F-63E5828EFDDBQ37375539-DB096F50-E2F8-4292-8B95-071E9D7CDE6FQ37466096-283AC3D3-28C5-465A-AD3B-40DC3807CAB2Q37563114-2E6F777D-C61D-4804-AEFA-CB81E7A7AFADQ37943719-8062A59F-75AE-4DB0-807A-D402E2672833Q37984287-D2243E1B-7E0D-4E03-9186-9EF7C7573E7F
P2860
Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@ast
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@en
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@nl
type
label
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@ast
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@en
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@nl
prefLabel
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@ast
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@en
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@nl
P2093
P2860
P356
P1433
P1476
Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.
@en
P2093
Chikao Morimoto
Eiji Takeda
Eri Sakamoto
Hajime Sasaki
Hideki Fujii
Jun Shirakawa
Kazutaka Aoki
Kei Ohnuma
Kikuko Amo
Koichiro Sato
P2860
P304
P356
10.2337/DB10-1338
P407
P577
2011-02-17T00:00:00Z